{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/331687663"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "ulatory approval of the Company's drug candidates, unexpected adverse side effects of the Company's drug candidates, unanticipated additional research and development and other costs, the potential for abuse resistant pain medications or other competing products or therapies to be developed by competitors and potential competitors or others; difficulties resulting from, or risks associated with, p" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "globenewswire.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/356843920"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/331687663"] } } }
